238 related articles for article (PubMed ID: 25038230)
1. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.
Baker GJ; Chockley P; Yadav VN; Doherty R; Ritt M; Sivaramakrishnan S; Castro MG; Lowenstein PR
Cancer Res; 2014 Sep; 74(18):5079-90. PubMed ID: 25038230
[TBL] [Abstract][Full Text] [Related]
2. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells.
Baker GJ; Chockley P; Zamler D; Castro MG; Lowenstein PR
Oncoimmunology; 2016 Jun; 5(6):e1163461. PubMed ID: 27471637
[TBL] [Abstract][Full Text] [Related]
4. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
5. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
Front Immunol; 2021; 12():668391. PubMed ID: 34539622
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
Yuan X; Hu J; Belladonna ML; Black KL; Yu JS
Cancer Res; 2006 Mar; 66(5):2630-8. PubMed ID: 16510582
[TBL] [Abstract][Full Text] [Related]
7. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.
Aulwurm S; Wischhusen J; Friese M; Borst J; Weller M
Int J Cancer; 2006 Apr; 118(7):1728-35. PubMed ID: 16217761
[TBL] [Abstract][Full Text] [Related]
8. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
[TBL] [Abstract][Full Text] [Related]
9. Enriched Environment Cues Suggest a New Strategy to Counteract Glioma: Engineered rAAV2-IL-15 Microglia Modulate the Tumor Microenvironment.
Mormino A; Bernardini G; Cocozza G; Corbi N; Passananti C; Santoni A; Limatola C; Garofalo S
Front Immunol; 2021; 12():730128. PubMed ID: 34552593
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiota alterations affect glioma growth and innate immune cells involved in tumor immunosurveillance in mice.
D'Alessandro G; Antonangeli F; Marrocco F; Porzia A; Lauro C; Santoni A; Limatola C
Eur J Immunol; 2020 May; 50(5):705-711. PubMed ID: 32034922
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
12. Experimental appraisal of the lack of antitumor natural killer cell-mediated immunosurveillance in response to lymphomas growing in the mouse brain.
Yamasaki T; Moritake K; Klein G
J Neurosurg; 2003 Mar; 98(3):599-606. PubMed ID: 12650434
[TBL] [Abstract][Full Text] [Related]
13. Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack.
Wang W; Guo H; Geng J; Zheng X; Wei H; Sun R; Tian Z
J Biol Chem; 2014 Nov; 289(48):33311-9. PubMed ID: 25315772
[TBL] [Abstract][Full Text] [Related]
14. Attribution of NKG2DL to the inhibition of early stage allogeneic tumors in mice.
Hua L; Fang M; Dong B; Guo S; Cui C; Liu J; Yao Y; Xiao Y; Li X; Ren Y; Meng X; Hao X; Zhao P; Song Y; Wang L; Yu Y
Oncotarget; 2016 Dec; 7(50):82369-82383. PubMed ID: 27448968
[TBL] [Abstract][Full Text] [Related]
15. Effective antitumor immunity against murine gliomas using dendritic cells transduced with hTERTC27 recombinant adenovirus.
Gong HX; He L; Li XP; Wang YD; Li Y; Huang JJ; Wang Z; Xie D; Kung HF; Peng Y
Oncol Rep; 2012 Apr; 27(4):1163-9. PubMed ID: 22210010
[TBL] [Abstract][Full Text] [Related]
16. Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines.
Ciaglia E; Laezza C; Abate M; Pisanti S; Ranieri R; D'alessandro A; Picardi P; Gazzerro P; Bifulco M
Int J Cancer; 2018 Jan; 142(1):176-190. PubMed ID: 28884474
[TBL] [Abstract][Full Text] [Related]
17. Autologous natural killer cell therapy for human recurrent malignant glioma.
Ishikawa E; Tsuboi K; Saijo K; Harada H; Takano S; Nose T; Ohno T
Anticancer Res; 2004; 24(3b):1861-71. PubMed ID: 15274367
[TBL] [Abstract][Full Text] [Related]
18. Galectin-1 and immunotherapy for brain cancer.
Verschuere T; De Vleeschouwer S; Lefranc F; Kiss R; Van Gool SW
Expert Rev Neurother; 2011 Apr; 11(4):533-43. PubMed ID: 21469926
[TBL] [Abstract][Full Text] [Related]
19. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
20. Effect of human interferon beta gene transfer upon human glioma, transplanted into nude mouse brain, involves induced natural killer cells.
Mizuno M; Yoshida J
Cancer Immunol Immunother; 1998 Dec; 47(4):227-32. PubMed ID: 9875676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
